Texas Health Atlas · San Antonio
bioAffinity Technologies
Develops tests that combine flow cytometry and AI to detect lung cancer early.
- Location
- San Antonio, Texas
- Focus
- Diagnostics, AI in healthcare
- Stage / status
- Commercial (per company)
- Notes
- Its CyPath Lung test analyzes a sputum sample collected at home.
- Website
- bioaffinitytech.com
- Last reviewed
- Sep 29, 2026
Coverage
The SignalAn FDA panel backed the first multi-cancer blood test. Here's what the data actually show.Advisers voted 7–2 that Galleri's benefits outweigh its risks. The FDA's own briefing shows a test that is very specific, finds about a third of cancers within a year, and raises questions nobody has answered yet.Future Health ExplainedWhat is a liquid biopsy?A liquid biopsy looks for cancer cells or tumor DNA in blood. How it's used to guide treatment and monitor cancer, what blood-based screening can and can't do yet, and where Texas companies fit.
Sources
Regulatory status is as stated by the company or its public filings on the review date; it changes. Work here? Send a correction or update.